BTS: Q3 weakness seems to improve already in Q4 - ABG
Q3 adj. EBITA -20% vs ABGSCe due to North America
Guides for recovery in Q4 and reiterates 2022 guidance
Estimates down somewhat, share to follow
Q3 details
Sales SEK 617m (-2% vs ABGSCe 628m, no cons), adj. EBITA 66m (-20% vs ABGSCe 64m), adj. EBITA margin 10.7% (ABGSCe 13.2%). FX adjusted growth 12% (vs ABGSCe 15%). North America sales in Q3 grew 1% FX adjusted, Europe 26% and Other markets 23%.
Länk till analysen i sin helhet: https://cr.abgsc.com/foretag/bts-group/Equity-research/2022/11/bts-group---q3-weakness-seems-to-improve-already-in-q4/